Ribociclib
Novartis
['breast', ' uc,(-ucsd),(-ucsf),']
 these landmark results will fundamentally change how we treat patients with stage ii and iii hr+/her2- early breast cancer who are in need of new, well-tolerated options that prevent their cancer from coming back, said the trial s lead investigator, dr. dennis slamon from ucla. 
We are accelerating discoveries to prevent and cure cancer.